📰 Markus Puhlmann News
Markus Puhlmann News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Markus Puhlmann. Real-time updates on events, politics, business and more.
April 18, 2024
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) fell 7.2% during mid-day trading on Tuesday . The stock traded as low as 1.42 and last traded at 1.42. 4,018,949 shares traded hands during trading, an increase of 8% from the average session volume of 3,734,385 shares. The stock had previously closed at 1.53. Analyst Upgrades […]
January 29, 2024
The Dow Jones index closed higher by around 60 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
January 27, 2024
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) insider Markus Puhlmann acquired 280,000 shares of the stock in a transaction on Wednesday, January 24th. The shares were acquired at an average price of 0.50 per share, with a total value of 140,000.00. Following the purchase, the insider now owns 1,375,425 shares in the company, valued […]
January 27, 2024
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) insider Markus Puhlmann bought 280,000 shares of the stock in a transaction dated Wednesday, January 24th. The stock was bought at an average price of 0.50 per share, with a total value of 140,000.00. Following the purchase, the insider now owns 1,375,425 shares of the company’s stock, […]
January 17, 2024
SEATTLE, Jan. 17, 2024 -- Perspective Therapeutics, Inc. , today announced that it began patient recruitment for the second dosing cohorts in clinical studies for both of its lead product...
January 5, 2024
Mayo Clinic’s PSMA Alpha-PET DoubLET platform allows for imaging and targeted therapy with alpha and/or beta-particle radiopharmaceutical therapy using a novel 64/67Cu and 203/212Pb double...
December 22, 2023
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) insider Markus Puhlmann purchased 60,419 shares of the company’s stock in a transaction on Monday, December 18th. The stock was acquired at an average price of 0.26 per share, for a total transaction of 15,708.94. Following the completion of the transaction, the insider now owns 695,425 shares […]
November 16, 2023
SEATTLE, Nov. 16, 2023 -- Perspective Therapeutics, Inc. , today announced the completion of cohort 1 dosing in the Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or...
October 16, 2023
SEATTLE, Oct. 16, 2023 -- Perspective Therapeutics, Inc. , today announced the completion of recruitment for the first patient cohort in its Phase 1/2a dose escalation study of 212Pb-VMT01 , its...
October 10, 2023
SEATTLE, Oct. 10, 2023 -- Perspective Therapeutics, Inc. , today announced that two upcoming investigator-initiated trials were presented at the North American Neuroendocrine Tumor Society ...